中西医药治疗自身免疫性肝病研究进展

doi:10.3969/j.issn.1672-5069.2020.03.038

摘要/Abstract

摘要： 目的自身免疫性肝病的发病率逐年升高,成为肝脏疾病的研究热点之一。西医治疗有明确的疗效,但中西医结合治疗能让患者有更多的获益,在提高治疗效果的同时,可以减少西药的副作用,提高西药的应答率,更好地改善患者的生存质量,延长生存时间。本文就当前西医、中医和中西医结合治疗进展进行了综述,以为临床提供可参考的中西医结合治疗方案。

关键词: 自身免疫性肝炎, 原发性胆汁性肝硬化, 原发性硬化性胆管炎, 中医药, 治疗 , ,

Abstract: Objective The morbidity of autoimmune liver disease (AILD) is increasing year by year, and it is one of the hotspots in research on liver diseases. Western medicine has definite curative efficacy, while it combines with traditional Chinese herbal medicine might benefit patients more by improving the efficacy, reducing side effects, improving patient's quality of life, and prolonging survival time. This article reviews the current progress on herbal and western medicine combination in treatment of patients with AILD.

Key words: Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis, Herbal medicine, Therapy

朱步坤,李刚,张玮. 中西医药治疗自身免疫性肝病研究进展[J]. 实用肝脏病杂志, 2020, 23(3): 453-456.

Zhu Bukun, Li Gang, Zhang Wei.. Chinese herbal and western medicine combination in treatment of patients with autoimmune liver disease[J]. Journal of Practical Hepatology, 2020, 23(3): 453-456.

参考文献

[1] Górski AE JończykMatysiak M, Szelachowska L, et al. Therapeutic potential of phages in autoimmune liver diseases. Clin Exp Immunol, 2018,192(1):1-6.
[2] Webb GJ, Hirschfield GM, Krawitt EL, et al. Cellular and molecular mechanisms of autoimmune hepatitis. Annu Rev Pathol,2018,13: 247-292.
[3] Wang Q, Yang F, Miao Q, et al.The clinical phenotypes of autoimmune hepatitis: A comprehensive review. J Autoimmun,2016,66: 98-107.
[4] Hennes E M, Zeniya M, Czaja A J, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48(1):169-176.
[5] Roberts SK, Kemp W.Salvage therapies for autoimmune hepatitis: A critical review.Sem Liver Dis,2017,37(4):343-362.
[6] 中华医学会肝病学分会.自身免疫性肝炎诊断和治疗共识(2015). 胃肠病学, 2016, 21(3):165-178.
[7] Czaja AJ. The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther,2014,39(4):385-406.
[8] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Autoimmune hepatitis.J Hepatol, 2015,63(4):971-1004.
[9] Purnak T, Efe C, Kav T, et al. Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis. Dig Dis Sci, 2017, 62(10):2900-2907.
[10] Tan P, Marotta P, Ghent C, et al. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int, 2005,25(4):728-733.
[11] Mendizabal M, Marciano S, Videla M G, et al. Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur J Gastroenterol Hepatol,2015,27(6):644-648.
[12] Peiseler M, Liebscher T, Sebode M, et al. Efficacy andlimitations of budesonide as a second-line treatment for patients with autoimmune hepatitis.Clin Gastroenterol Hepatol, 2018,16(2):260-267.
[13] Woynarowski M, Nemeth A, Baruch Y, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr,2013,163(5):1347-1353.
[14] Zachou K, Gatselis N, Papadamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-native patients.J Hepatol,2011,55(3):636-646.
[15] Liwinski T,Schramm C. Autoimmune hepatitis -update on clinical management in 2017. Clin Res Hepatol Gastroenterol,2017,41(6):617-625.
[16] Burak K W, Swain M G, Santodomino-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol,2013,27(5):273-280.
[17] 张玮, 刘一博, 王俐琼,等. 调免Ⅰ号联合熊去氧胆酸胶囊治疗自身免疫性肝炎的临床观察. 中西医结合肝病杂志, 2009, 19(2):78-80.
[18] 王艳丽, 吴东. 中西医结合治疗自身免疫性肝炎临床观察. 湖北中医杂志, 2013, 35(11):18-19.
[19] 张红星, 刘旭东. 中西医结合治疗自身免疫性肝炎30例观察. 实用中医药杂志, 2016, 32(6):555-556.
[20] Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis.Lancet, 2015, 386(10003):1565-1575.
[21] Hirschfield GM, Beuers U, Corpechot C, et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.J Hepatol,2017,67(1):145-172.
[22] Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology, 2006,130(3):715-720.
[23] Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int, 2015, 35(2):636-641.
[24] Ter Borg P C, Schalm S W, Hansen B E, et al. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol,2006,101(9):2044-2050.
[25] Zhu G Q, Shi K Q, Huang S, et al. Network Meta-analysis of randomized controlled trials: Efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine, 2015, 94(11):e609.
[26] Hirschfield G M, Mason A, Luketic V, et al. Efficacy ofobeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology,2015,148(4):751-761.